Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review.

ABSTRACT: Growing research has focused on obesity as a prognostic factor during therapy with immune-checkpoint inhibitors (ICIs). The role of body-mass index (BMI) in predicting response and toxicity to ICIs is not clear, as studies have shown inconsistent results and significant interpretation biases. We performed a systematic review to evaluate the relationship between BMI and survival outcomes during ICIs, with a side focus on the incidence of immune-related adverse events (irAEs). A total of 17 studies were included in this systematic review. Altogether, the current evidence does not support a clearly positive association of BMI with survival outcomes. Regarding toxicities, available studies confirm a superimposable rate of irAEs among obese and normal weight patients. Intrinsic limitations of t

SUBMITTER: Indini A 

PROVIDER: S-EPMC7961496 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature